Effectiveness of BCG vaccination among leprosy contacts: a cohort study.

Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: an overview. Future Microbiol (2011) 1.00

Impact of PGL-I seropositivity on the protective effect of BCG vaccination among leprosy contacts: a cohort study. PLoS Negl Trop Dis (2012) 0.93

Leprosy among patient contacts: a multilevel study of risk factors. PLoS Negl Trop Dis (2011) 0.92

The combined effect of chemoprophylaxis with single dose rifampicin and immunoprophylaxis with BCG to prevent leprosy in contacts of newly diagnosed leprosy cases: a cluster randomized controlled trial (MALTALEP study). BMC Infect Dis (2013) 0.90

Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection. Infect Immun (2009) 0.89

Advances and hurdles on the way toward a leprosy vaccine. Hum Vaccin (2011) 0.87

Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy. Risk Manag Healthc Policy (2016) 0.75

Interruption of persistent exposure to leprosy combined or not with recent BCG vaccination enhances the response to Mycobacterium leprae specific antigens. PLoS Negl Trop Dis (2017) 0.75

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med (1991) 4.43

Study designs for dependent happenings. Epidemiology (1991) 3.58

The cutaneous infiltrates of leprosy: cellular characteristics and the predominant T-cell phenotypes. N Engl J Med (1982) 3.52

Causal inference in infectious diseases. Epidemiology (1995) 3.21

Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2. J Exp Med (1983) 2.61

Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol (1997) 2.26

Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int J Epidemiol (1995) 2.25

Acute retrovirus syndrome among prospectively identified homosexual men with incident HIV infection in Brazil. Projecto Praça Onze Study Group. J Acquir Immune Defic Syndr (2000) 2.19

Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients. Am J Pathol (1987) 2.18

Influence of delayed immune reactions on human epidermal keratinocytes. Proc Natl Acad Sci U S A (1986) 2.11

Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol (1991) 2.08

Design and interpretation of vaccine field studies. Epidemiol Rev (1999) 1.76

Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med (1992) 1.63

The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis (1993) 1.55

The cutaneous infiltrates of leprosy. A transmission electron microscopy study. J Exp Med (1983) 1.51

[Progression to IDDM and islet cell antibodies (ICA; ICA-CF)]. J Pediatr (Rio J) (2003) 1.39

Estimability and interpretation of vaccine efficacy using frailty mixing models. Am J Epidemiol (1996) 1.37

Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther (2008) 1.27

Use of ML dipstick as a tool to classify leprosy patients. Int J Lepr Other Mycobact Dis (2000) 1.16

CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients. Clin Pharmacol Ther (2013) 1.12

Epidemiologic effects of vaccines with complex direct effects in an age-structured population. Math Biosci (1994) 1.11

Cellular immune response to Mycobacterium leprae infection in human immunodeficiency virus-infected individuals. Infect Immun (1995) 1.10

Immunological cytokine correlates of protective immunity and pathogenesis in leprosy. Scand J Immunol (2000) 1.10

Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). Scand J Immunol (1999) 1.09

Reactional states in multibacillary Hansen disease patients during multidrug therapy. Rev Inst Med Trop Sao Paulo (1999) 1.09

Impact of insecticide interventions on the abundance and resistance profile of Aedes aegypti. Epidemiol Infect (2009) 1.03

Modeling malaria vaccines. II: Population effects of stage-specific malaria vaccines dependent on natural boosting. Math Biosci (1989) 1.03

Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. Genes Immun (2004) 1.02

A non-parametric method for the reconstruction of age- and time-dependent incidence from the prevalence data of irreversible diseases with differential mortality. Theor Popul Biol (1999) 1.01

Use of PCR-mediated amplification of Mycobacterium leprae DNA in different types of clinical samples for the diagnosis of leprosy. J Med Microbiol (1993) 1.01

[Leprosy epidemiology in a cohort of household contacts in Rio de Janeiro (1987-1991)]. Cad Saude Publica (2000) 0.99

IFNG +874 T>A single nucleotide polymorphism is associated with leprosy among Brazilians. Hum Genet (2010) 0.99

Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin Exp Immunol (1998) 0.96

Serological response of patients with leprosy to a 28- to 30-kilodalton protein doublet from early cultures of Mycobacterium bovis BCG. J Clin Microbiol (1989) 0.96

Risk assessment of yellow fever urbanization in Rio de Janeiro, Brazil. Trans R Soc Trop Med Hyg (2004) 0.96

HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients. Genes Immun (2007) 0.94

Leprosy and AIDS: two cases of increasing inflammatory reactions at the start of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis (2004) 0.93

Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther (2010) 0.93

High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine (2009) 0.93

T cell immune responses to mycobacterial antigens in Brazilian tuberculosis patients and controls. Trans R Soc Trop Med Hyg (2005) 0.92

The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression. Clin Exp Immunol (2011) 0.92

Bacterial and host-derived cationic proteins bind alpha2-laminins and enhance Mycobacterium leprae attachment to human Schwann cells. Microbes Infect (2000) 0.92

M. leprae-HIV co-infection: pattern of immune response in vivo and in vitro. Indian J Lepr (2000) 0.92

Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharmacogenomics J (2010) 0.92

Modeling transmission dynamics of stage-specific malaria vaccines. Parasitol Today (1992) 0.91

Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30-kilodalton proteins purified from Mycobacterium bovis BCG. J Clin Microbiol (1991) 0.91

Positive selection drives accelerated evolution of mosquito salivary genes associated with blood-feeding. Insect Mol Biol (2013) 0.91

Circling spreading depression in isolated chick retina. J Neurophysiol (1974) 0.90

Neutrophils isolated from leprosy patients release TNF-alpha and exhibit accelerated apoptosis in vitro. J Leukoc Biol (1999) 0.89

Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro. Biomed Pharmacother (2002) 0.89

Risk of tuberculous infection in an indigenous population from Amazonia, Brazil. Int J Tuberc Lung Dis (2006) 0.89

Extensive Mycobacterium tuberculosis circulation in a highly endemic prison and the need for urgent environmental interventions. Epidemiol Infect (2011) 0.89

Binding of alpha2-laminins by pathogenic and non-pathogenic mycobacteria and adherence to Schwann cells. J Med Microbiol (2001) 0.89

Effect of treatment on the cellular composition of cutaneous lesions in leprosy patients. Int J Lepr Other Mycobact Dis (1984) 0.89

Induction of apoptosis in monocytes by Mycobacterium leprae in vitro: a possible role for tumour necrosis factor-alpha. Immunology (2003) 0.88

Limited-sampling strategy models for estimating the area under the plasma concentration-time curve for amlodipine. Eur J Clin Pharmacol (1999) 0.87

Thalidomide protects mice against LPS-induced shock. Braz J Med Biol Res (1997) 0.87

Modeling malaria vaccines. I: New uses for old ideas. Math Biosci (1989) 0.87

DC-SIGN association with the Th2 environment of lepromatous lesions: cause or effect? J Pathol (2006) 0.87

An immunohistochemical, clinical and electroneuromyographic correlative study of the neural markers in the neuritic form of leprosy. Braz J Med Biol Res (2006) 0.86

Influence of Mycobacterium leprae and its soluble products on the cutaneous responsiveness of leprosy patients to antigen and recombinant interleukin 2. Proc Natl Acad Sci U S A (1989) 0.86

High prevalence of vasomotor reflex impairment in newly diagnosed leprosy patients. Eur J Clin Invest (2005) 0.86

Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient. Br J Dermatol (2001) 0.86

Limited-sampling strategy models for itraconazole and hydroxy-itraconazole based on data from a bioequivalence study. Antimicrob Agents Chemother (1999) 0.86

CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. Pharmacogenomics J (2005) 0.86

Vaccine-associated paralytic poliomyelitis: a retrospective cohort study of acute flaccid paralyses in Brazil. Int J Epidemiol (2000) 0.85

Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine (2012) 0.85

Anti-inflammatory drugs block cytokine mRNA accumulation in the skin and improve the clinical condition of reactional leprosy patients. J Invest Dermatol (2000) 0.85

Development and validation of limited-sampling strategies for predicting amoxicillin pharmacokinetic and pharmacodynamic parameters. Antimicrob Agents Chemother (2001) 0.85

Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field. Stat Med (1994) 0.85

Effect of unique Mycobacterium leprae phenolic glycolipid-I (PGL-I) on tumour necrosis factor production by human mononuclear cells. Lepr Rev (2001) 0.85

Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy. Braz J Med Biol Res (2007) 0.84

Expression and cytokine secretion in the states of immune reactivation in leprosy. Braz J Med Biol Res (1998) 0.83

Rate estimation from prevalence information on a simple epidemiologic model for health interventions. Theor Popul Biol (1996) 0.83

Long-term culture of multibacillary leprosy macrophages isolated from skin lesions: a new model to study Mycobacterium leprae-human cell interaction. Br J Dermatol (2007) 0.83

In vitro tumor necrosis factor production by mononuclear cells from lepromatous leprosy patients and from patients with erythema nodosum leprosum. Clin Immunol Immunopathol (1993) 0.83

Mycobacterium leprae-induced interferon-gamma production by household contacts of leprosy patients: association with the development of active disease. J Infect Dis (1991) 0.83

On the distribution of vaccine protection under heterogeneous response. Math Biosci (1993) 0.83

Different immunosuppressive mechanisms in multi-drug-resistant tuberculosis and non-tuberculous mycobacteria patients. Clin Exp Immunol (2013) 0.82

Patterns of intracellular cytokines in CD4 and CD8 T cells from patients with mycobacterial infections. Braz J Med Biol Res (2004) 0.82

Detection of in vitro interferon-gamma and serum tumour necrosis factor-alpha in multidrug-resistant tuberculosis patients. Clin Exp Immunol (2005) 0.82

The impact of imperfect vaccines on the evolution of HIV virulence. Med Hypotheses (2006) 0.81

Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. Immunogenetics (2001) 0.81

Effect of treatment on immune responsiveness in lepromatous leprosy patients. Lepr Rev (1990) 0.81

Impairments in multibacillary leprosy; a study from Brazil. Lepr Rev (2004) 0.81

A modelling analysis of pertussis transmission and vaccination in Rio de Janeiro, Brazil. Epidemiol Infect (2005) 0.80

The use of pentoxifylline in the treatment of type 2 reactional episodes in leprosy. Indian J Lepr (2001) 0.80

T-helper cell subpopulations and the immune spectrum of leprosy. Int J Lepr Other Mycobact Dis (1989) 0.80

Increased Langerhans cell accumulation after mycobacterial stimuli. Histopathology (2007) 0.80

Interleukin-10-dependent down-regulation of interferon-gamma response to Leishmania by Mycobacterium leprae antigens during the clinical course of a coinfection. Braz J Med Biol Res (2012) 0.80